However, in a preclinical study FGF23 monoclonal antibodies applied in a rat model of CKD-mineral and bone disorder led to normalization of bone and mineral markers but increased aortic calcification and mortality, probably due to an incapacity to excrete phosphate, which was already impaired due to the CKD background [78]. The gene discussed is FGF23; the disease is chronic kidney disease.